Therapeutic Delivery Platforms against Botulism
针对肉毒杆菌中毒的治疗递送平台
基本信息
- 批准号:8366528
- 负责人:
- 金额:$ 19.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-06-01 至 2014-05-31
- 项目状态:已结题
- 来源:
- 关键词:ADP Ribose TransferasesAdjuvantAffinityBindingBinding SitesBiologicalBiological AssayBontoxilysinBotulismCategoriesCellsCholera ToxinCholera Toxin Protomer BComplexCytosolEngineeringEnterotoxinsEscherichia coliEscherichia coli heat-labile toxinGT1b gangliosideGangliosidesGreen Fluorescent ProteinsHeatingHumanImmuneImmune responseKnowledgeMeasuresMotor NeuronsMusMutateNervous system structureNeuronsParalysedPentasPoint MutationPropertyProteinsProteolysisReagentS-nitro-N-acetylpenicillamineSerotypingSite-Directed MutagenesisTestingTherapeuticToxic effectToxinVaccinesbaseeffective therapyhuman diseaseinhibitor/antagonistnervous system disorderprotein structure functionprototyperesearch studysuccesstarget SNARE proteinstrafficking
项目摘要
DESCRIPTION (provided by applicant): The botulinum neurotoxins (BoNTs) are the most potent protein toxins for humans and Category A select agents. There are seven serotypes of the BoNTs (termed A-G). The current penta-serotype vaccine is in limited supply and there are no approved therapies against botulism. During studies on BoNT entry into neurons, the B subunit of cholera toxin (CTB) was observed to enter BoNT-intoxicated neurons with the same efficiency as untreated cells. Since cholera toxin has been used to deliver heterologous proteins into cells, CTB or a related B subunit of the heat-labile enterotoxins of Escherichia coli (LTB) wil be developed as a platform to deliver therapies into BoNT-intoxicated neurons. The R21 component is a proof of concept to engineer a B subunit-based platform to deliver a heterologous cargo into the cytosol of a BoNT- intoxicated neuron. There are three aims: identify the most efficient B subunit for entry into BoNT-intoxicated neurons, engineer a cargo-A2 linker to assemble onto the B subunit delivery platform, and determine if the B subunit platform can deliver cargo into a BoNT-intoxicated neuron. The R33 component will optimize the B subunit as a therapy. There are 3 aims: optimize entry of the B subunit platform into neurons, optimize the cargo-A2 linker for assembly onto the B subunit platform, and deliver a pan-serotype therapy into a BoNT-intoxicated neuron and test this therapy in BoNT-intoxicated mice. Completion of this proposal will provide a platform for therapies against botulism that may also be useful as a delivery platform to treat other infectious neurological diseases and diseases of the nervous system.
PUBLIC HEALTH RELEVANCE: The botulinum neurotoxins (BoNTs) are the most toxic proteins for humans. The determination that the B subunit of cholera toxin enters BoNT-intoxicated neurons provides a basis to develop a platform to deliver therapies to treat BoNT-intoxicated cells to reverse the paralysis associated with botulism. This platform may also have utility to deliver therapies against other neurological diseases.
描述(由申请方提供):肉毒杆菌神经毒素(BoNT)是对人类最有效的蛋白质毒素,是A类选择剂。BoNT有七种血清型(称为A-G)。目前的五血清型疫苗供应有限,并且没有批准的针对肉毒杆菌中毒的疗法。在对BoNT进入神经元的研究中,观察到霍乱毒素的B亚单位(CT B)以与未处理的细胞相同的效率进入BoNT中毒的神经元。由于霍乱毒素已被用于将异源蛋白递送到细胞中,因此将开发大肠杆菌(LTB)的热不稳定肠毒素的CT B或相关B亚基作为将治疗递送到BoNT中毒的神经元中的平台。R21组分是设计基于B亚基的平台以将异源货物递送到BoNT中毒的神经元的胞质溶胶中的概念验证。有三个目标:鉴定进入BoNT-中毒的神经元的最有效的B亚基,工程化货物-A2接头以组装到B亚基递送平台上,并确定B亚基平台是否可以将货物递送到BoNT-中毒的神经元中。R33组分将优化B亚基作为治疗。有三个目标:优化B亚基平台进入神经元,优化货物-A2接头以组装到B亚基平台上,并将泛血清型疗法递送到BoNT中毒的神经元中,并在BoNT中毒的小鼠中测试该疗法。该提案的完成将为肉毒杆菌中毒的治疗提供一个平台,该平台也可用作治疗其他传染性神经系统疾病和神经系统疾病的递送平台。
公共卫生相关性:肉毒杆菌神经毒素(BoNT)是对人类毒性最大的蛋白质。确定霍乱毒素的B亚基进入BoNT-中毒的神经元提供了开发平台的基础,该平台用于递送治疗BoNT-中毒的细胞的疗法以逆转与肉毒中毒相关的麻痹。该平台还可以用于提供针对其他神经系统疾病的治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph T Barbieri其他文献
Joseph T Barbieri的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph T Barbieri', 18)}}的其他基金
Characteristics of Botulinum Neurotoxins that determine potency
决定效力的肉毒杆菌神经毒素的特征
- 批准号:
10539300 - 财政年份:2019
- 资助金额:
$ 19.13万 - 项目类别:
Characteristics of Botulinum Neurotoxins that determine potency
决定效力的肉毒杆菌神经毒素的特征
- 批准号:
10326384 - 财政年份:2019
- 资助金额:
$ 19.13万 - 项目类别:
Therapeutic Delivery Platforms against Botulism
针对肉毒杆菌中毒的治疗递送平台
- 批准号:
8468641 - 财政年份:2012
- 资助金额:
$ 19.13万 - 项目类别:
Characterization of botulinum neurotoxin A subtypes
肉毒杆菌神经毒素 A 亚型的表征
- 批准号:
9542546 - 财政年份:2012
- 资助金额:
$ 19.13万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 19.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 19.13万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 19.13万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 19.13万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 19.13万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 19.13万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 19.13万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 19.13万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 19.13万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 19.13万 - 项目类别: